Summary

Dual antiplatelet therapy in patients with acute coronary syndromes is becoming more complex, making it difficult to select the optimal therapy. The optimal regimen; the potential risk for adverse events, bleeding in particular; and the role of genotyping are among the most important questions that remain unanswered.